MRNA Pre-tax Income History: $-2.77B (FY2025)

Fiscal year	Q1	Q2	Q3	Q4
FY26	−$1.3B−38.4%	Not reported	Not reported	Not reported
FY25	−$964M+17.3%	−$818M+36.0%	−$187M−990.5%	−$799M+32.5%
FY24	−$1.2B−282.0%	−$1.3B+26.9%	$21M+101.1%	−$1.2B−1791.4%
FY23	−$305M−107.2%	−$1.7B−170.7%	−$2.0B−260.9%	$70M−95.8%
FY22	$4.2B+235.6%	$2.5B−19.2%	$1.2B−65.7%	$1.7B−69.4%
Share	27%	24%	20%	29%

01—History

Pre-tax Income History

Year-over-year comparison from 10-K annual reports · Dashed line: constant growth FY2020–FY2025. Drag across the bars to change the range.

−$2.77B

YoY changeLargest recent move−44.6%in FY20Latest +23.3%

1 older move runs past ±150% (largest +1884.4%); point at, tap or drag across the bars to read one.

02—Ledger

Pre-tax Income, period by period

Period	Value	Change	Source
FY2025	−$2.77B	+23.3%	10-K
FY2024	−$3.61B	+8.5%	10-K
FY2023	−$3.94B	−141.2%	10-K
FY2022	$9.57B	−27.9%	10-K
FY2021	$13.29B	+1884.4%	10-K
FY2020	−$744.5M	−44.6%	10-K
FY2019	−$514.7M	−33.9%	10-K
FY2018	−$384.4M	−50.2%	10-K
FY2017	−$256.0M	−19.0%	10-K
FY2016	−$215.2M	—	10-K

03—Questions

What is Moderna, Inc.'s current pre-tax income?

Moderna, Inc. (MRNA) annual pre-tax income for 2025 was $-2.77B, a 23.26% increase from 2024. Moderna, Inc. pre-tax income for the quarter ending March 31, 2026 was $-1.33B.

What was Moderna, Inc.'s pre-tax income in 2024?

Moderna, Inc. annual pre-tax income for 2024 was $-3.61B, a 8.50% increase from 2023.

What was Moderna, Inc.'s pre-tax income in 2023?

Moderna, Inc. annual pre-tax income for 2023 was $-3.94B, a 141.17% decline from 2022.

Company: Moderna, Inc.
Ticker: MRNA
Sector: Healthcare
Industry: Biological Products, (No Diagnostic Substances)

Moderna, Inc. Pre-tax Income 2016-2026 | MRNA

Key Statistics